@Article{oncologie.2020.012485,
AUTHOR = {Hao Dang},
TITLE = {Diagnostic Performance of Serum miR-586 and miR-493 in Patients with  Osteosarcoma},
JOURNAL = {Oncologie},
VOLUME = {22},
YEAR = {2020},
NUMBER = {1},
PAGES = {35--42},
URL = {http://www.techscience.com/oncologie/v22n1/39629},
ISSN = {1765-2839},
ABSTRACT = {This study aimed to explore the expression and diagnostic performance 
of miR-586 and miR-493 in patients with osteosarcoma. We enrolled 63 patients 
with osteosarcoma treated between May 2016 and May 2019 as the experimental 
group and 55 healthy volunteers who underwent physical examination during the 
same period as the control group. We detected miR-586 and miR-493 expression 
in serum, normal bone tissue, and tumor samples. We also evaluated the 
relationship between clinical indicators and the miR-586 and miR-493 expression 
levels. The correlation between the serum and osteosarcoma tissue expression of 
miR-586 and miR-493 was examined by Pearson analysis. Furthermore, the 
diagnostic performance of miR-586 and miR-493 in osteosarcoma was determined
by the ROC curve analysis. The experimental group had higher serum miR-586 
expression levels and lowered serum miR-493 expression levels than the control 
group (<i>p</i> < 0.05 on both). In tumor tissues, the miR-586 expression level was 
higher, whereas the miR-493 expression level was lower than in normal bone 
tissues (<i>p</i> < 0.05). The serum and tumor tissue expression of miR-586 and miR-
493 had a positive correlation (<i>p</i> < 0.05). The AUC, cutoff level, sensitivity, and 
specificity of miR-586 for osteosarcoma were 0.8413, 66.435, 66.67, and 98.18, 
whereas those of miR-493 were 0.7763, 62.540, 82.53, and 78.18, respectively. 
Patients with osteosarcoma exhibited up-regulated miR-586 levels and downregulated miR-493 levels in serum and tumor tissues significantly.},
DOI = {10.32604/oncologie.2020.012485}
}